Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Inventory (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Inventory for 4 consecutive years, with $365000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Inventory rose 55.98% to $365000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $365000.0, a 55.98% increase, with the full-year FY2024 number at $173000.0, up 18.49% from a year prior.
  • Inventory was $365000.0 for Q3 2025 at Orchestra BioMed Holdings, up from $185000.0 in the prior quarter.
  • In the past five years, Inventory ranged from a high of $365000.0 in Q3 2025 to a low of $70000.0 in Q2 2024.
  • A 4-year average of $187166.7 and a median of $175500.0 in 2023 define the central range for Inventory.
  • Peak YoY movement for Inventory: crashed 60.67% in 2024, then skyrocketed 164.29% in 2025.
  • Orchestra BioMed Holdings' Inventory stood at $276000.0 in 2022, then plummeted by 47.1% to $146000.0 in 2023, then grew by 18.49% to $173000.0 in 2024, then surged by 110.98% to $365000.0 in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Inventory are $365000.0 (Q3 2025), $185000.0 (Q2 2025), and $135000.0 (Q1 2025).